Tag Archive for: transmucosal buprenorphine product

Brixadi’s extended-release feature distinguishes it from existing treatment options that typically require daily dosing. The drug also stands to improve patient adherence to treatment plans by eliminating the need for frequent administration, a common stumbling block.